Results 171 to 180 of about 6,879 (203)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2004
Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003.
Jose R, Fernandez, David B, Allison
openaire +1 more source
Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003.
Jose R, Fernandez, David B, Allison
openaire +1 more source
Efficacy and Safety of the Weight-Loss Drug Rimonabant: A Meta-Analysis of Randomised Trials
Lancet, The, 2007Arne Astrup +2 more
exaly

